Genmab (GMAB) Fundamental Analysis: Revenue, Earnings & Valuation

7.02 / 10

Outperform

Fundamental rating is Outperform with a 7.0/10 score. Strong points include low cost‑of‑sales (6.4%), solid interest coverage (35.1x), robust YoY revenue growth (~19%), and efficient inventory turnover (17.6). Asset‑MV and Revenue‑MV are slightly negative but high‑quality, supporting an optimistic outlook.

Analysis Checks(10/10)

Revenue-MV

Value-0.55

Score3/3

Weight27.53%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value19.19

Score2/3

Weight0.38%

1M Return0.13%

Inventory turnover ratio

Value17.63

Score2/3

Weight-3.14%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value20.31

Score2/3

Weight1.06%

1M Return0.36%

PB-ROE

Value0.52

Score2/3

Weight25.68%

1M Return7.29%

Long-term debt to working capital ratio (%)

Value3.84

Score3/3

Weight2.41%

1M Return0.87%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-3.19%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value19.19

Score2/3

Weight0.15%

1M Return0.05%

Cost of sales ratio (%)

Value6.40

Score3/3

Weight0.80%

1M Return0.26%

Asset-MV

Value-0.55

Score3/3

Weight48.33%

1M Return11.61%

Is GMAB fundamentally strong?

GMAB scores 7.02/10 on fundamentals and holds a Discounted valuation at present. Backed by its 17.53% ROE, 25.89% net margin, 17.23 P/E ratio, 2.84 P/B ratio, and -12.23% earnings growth, these metrics solidify its Outperform investment rating.